{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T19:05:40Z","timestamp":1772651140191,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint inhibitors (ICIs), particularly PD-1\/PD-L1 blockade, represent a cornerstone of treatment for advanced gastric cancer (GC). However, their clinical efficacy is hampered by low response rates and the development of both primary and acquired resistance, underscoring the need for innovative combination therapies. In this study, we investigate the potential of Ubenimex, an immunomodulator and inhibitor of leucyl aminopeptidase 3 (LAP3), in enhancing the therapeutic efficacy of PD-L1 blockade in GC. Using a syngeneic GC mouse model, we demonstrate that Ubenimex significantly augments the efficacy of anti-PD-L1 therapy. We further explore the role of LAP3 in GC progression and find that it is highly expressed in both GC tissues and cells, with elevated LAP3 levels correlating with poor prognosis. Functionally, LAP3 facilitates immune evasion through impaired CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell infiltration and cytotoxicity in the GC tumor microenvironment (TME). Notably, our findings reveal that LAP3 enhances PD-L1 expression by binding to UBE3A, an E3 ubiquitin ligase. Ubenimex disrupts the LAP3-UBE3A interaction, leading to restored UBE3A-mediated ubiquitination and degradation of PD-L1. This mechanism reinvigorates CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell infiltration and cytotoxic activity within the TME, thereby overcoming resistance to anti-PD-L1 therapy. In conclusion, our study provides a strong rationale for the synergistic potential of Ubenimex in combination with PD-1\/PD-L1 blockade, offering a promising strategy to overcome current limitations of ICIs therapy in GC patients.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08509-3","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:27:30Z","timestamp":1772119650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ubenimex synergizes with the PD-L1 blockade in gastric cancer by competitively binding LAP3 with UBE3A"],"prefix":"10.1038","volume":"17","author":[{"given":"Caixia","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8366-265X","authenticated-orcid":false,"given":"Jiaxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxiu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Che","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Likun","family":"Zan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujing","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0273-1505","authenticated-orcid":false,"given":"Lijun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-7330","authenticated-orcid":false,"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"8509_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00720-8","volume":"13","author":"N Qin","year":"2025","unstructured":"Qin N, Fan Y, Yang T, Yang Z, Fan D. The burden of Gastric Cancer and possible risk factors from 1990 to 2021, and projections until 2035: findings from the Global Burden of Disease Study 2021. Biomark Res. 2025;13:5.","journal-title":"Biomark Res"},{"key":"8509_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","volume":"22","author":"AVR Kornepati","year":"2022","unstructured":"Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022;22:174\u201389.","journal-title":"Nat Rev Cancer"},{"key":"8509_CR3","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402:2197\u2013208.","journal-title":"Lancet"},{"key":"8509_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","volume":"31","author":"L Shen","year":"2025","unstructured":"Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025;31:1163\u201370.","journal-title":"Nat Med"},{"key":"8509_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1210164","volume":"14","author":"G Mestrallet","year":"2023","unstructured":"Mestrallet G, Brown M, Bozkus CC, Bhardwaj N. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors. Front Immunol. 2023;14:1210164.","journal-title":"Front Immunol"},{"key":"8509_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s11684-022-0922-5","volume":"16","author":"Y Yu","year":"2022","unstructured":"Yu Y. Multi-target combinatory strategy to overcome tumor immune escape. Front Med. 2022;16:208\u201315.","journal-title":"Front Med"},{"key":"8509_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41419-025-07385-7","volume":"16","author":"D Luo","year":"2025","unstructured":"Luo D, Zhou J, Ruan S, Zhang B, Zhu H, Que Y, et al. Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies. Cell Death Dis. 2025;16:75.","journal-title":"Cell Death Dis"},{"key":"8509_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely MD, Zhang T, Chen L. Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annu Rev Immunol. 2022;40:45\u201374.","journal-title":"Annu Rev Immunol"},{"key":"8509_CR9","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","volume":"42","author":"C Galassi","year":"2024","unstructured":"Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell. 2024;42:1825\u201363.","journal-title":"Cancer Cell"},{"key":"8509_CR10","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/cancers13040663","volume":"13","author":"Y Yuan","year":"2021","unstructured":"Yuan Y, Adam A, Zhao C, Chen H. Recent Advancements in the Mechanisms Underlying Resistance to PD-1\/PD-L1 Blockade Immunotherapy. Cancers. 2021;13:663.","journal-title":"Cancers"},{"key":"8509_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","volume":"30","author":"F Wang","year":"2024","unstructured":"Wang F, Jin Y, Wang M, Luo HY, Fang WJ, Wang YN, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial. Nat Med. 2024;30:1035\u201343.","journal-title":"Nat Med"},{"key":"8509_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40164-021-00213-6","volume":"10","author":"S Okabe","year":"2021","unstructured":"Okabe S, Tanaka Y, Gotoh A. Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma. Exp Hematol Oncol. 2021;10:19.","journal-title":"Exp Hematol Oncol"},{"key":"8509_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","volume":"17","author":"MQ Shi","year":"2024","unstructured":"Shi MQ, Xu Y, Fu X, Pan DS, Lu XP, Xiao Y, et al. Advances in targeting histone deacetylase for treatment of solid tumors. J Hematol Oncol. 2024;17:37.","journal-title":"J Hematol Oncol"},{"key":"8509_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1170207","volume":"14","author":"C Shen","year":"2023","unstructured":"Shen C, Li M, Duan Y, Jiang X, Hou X, Xue F, et al. HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma. Front Immunol. 2023;14:1170207.","journal-title":"Front Immunol"},{"key":"8509_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/sj.leu.2401388","volume":"13","author":"K Sekine","year":"1999","unstructured":"Sekine K, Fujii H, Abe F. Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia. 1999;13:729\u201334.","journal-title":"Leukemia"},{"key":"8509_CR16","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1096\/fj.11-181396","volume":"25","author":"M Piedfer","year":"2011","unstructured":"Piedfer M, Dauzonne D, Tang R, N\u2019Guyen J, Billard C, Bauvois B. Aminopeptidase-N\/CD13 is a potential proapoptotic target in human myeloid tumor cells. FASEB J. 2011;25:2831\u201342.","journal-title":"FASEB J"},{"key":"8509_CR17","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.2147\/CMAR.S300515","volume":"13","author":"X Liu","year":"2021","unstructured":"Liu X, Guo Q, Jing F, Zhou C, Xiu T, Shi Y, et al. Ubenimex Suppresses the Ability of Migration and Invasion in Gastric Cancer Cells by Alleviating the Activity of the CD13\/NAB1\/MAPK Pathway. Cancer Manag Res. 2021;13:4483\u201395.","journal-title":"Cancer Manag Res"},{"key":"8509_CR18","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.21037\/tcr-23-435","volume":"12","author":"Y Shi","year":"2023","unstructured":"Shi Y, Guo Q, Jing F, Shang X, Zhou C, Jing F. Ubenimex suppresses glycolysis mediated by CD13\/Hedgehog signaling to enhance the effect of cisplatin in liver cancer. Transl Cancer Res. 2023;12:2823\u201336.","journal-title":"Transl Cancer Res"},{"key":"8509_CR19","first-page":"206","volume":"31","author":"X Hu","year":"2021","unstructured":"Hu X, Xiong H, Huang S, Mao T, Yang L, Su T. Efficacy of Standardised Treatments Combined with Ubenimex in Patients with Malignant Tumors. J Coll Phys Surg Pak. 2021;31:206\u20139.","journal-title":"J Coll Phys Surg Pak"},{"key":"8509_CR20","first-page":"1563","volume":"14","author":"M Iwahashi","year":"1994","unstructured":"Iwahashi M, Tanimura H, Yamaue H, Tani M, Noguchi K, Mizobata S, et al. Ubenimex treatment enhances the susceptibility of gastric cancer cell lines to lymphokine-activated killer cells. Anticancer Res. 1994;14:1563\u20138.","journal-title":"Anticancer Res"},{"key":"8509_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF00205548","volume":"23","author":"K Ota","year":"1986","unstructured":"Ota K, Kurita S, Yamada K, Masaoka T, Uzuka Y, Ogawa N. Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults. Cancer Immunol Immunother. 1986;23:5\u201310.","journal-title":"Cancer Immunol Immunother"},{"key":"8509_CR22","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1515\/BC.2006.191","volume":"387","author":"M Matsui","year":"2006","unstructured":"Matsui M, Fowler JH, Walling LL. Leucine aminopeptidases: diversity in structure and function. Biol Chem. 2006;387:1535\u201344.","journal-title":"Biol Chem"},{"key":"8509_CR23","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1046\/j.0014-2956.2001.02713.x","volume":"269","author":"T Ishizaki","year":"2002","unstructured":"Ishizaki T, Tosaka A, Nara T, Aoshima N, Namekawa S, Watanabe K, et al. Leucine aminopeptidase during meiotic development. Eur J Biochem. 2002;269:826\u201332.","journal-title":"Eur J Biochem"},{"key":"8509_CR24","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.18632\/aging.204011","volume":"14","author":"L Feng","year":"2022","unstructured":"Feng L, Chen Y, Xu K, Li Y, Riaz F, Lu K, et al. Cholesterol-induced leucine aminopeptidase 3 (LAP3) upregulation inhibits cell autophagy in pathogenesis of NAFLD. Aging. 2022;14:3259\u201375.","journal-title":"Aging"},{"key":"8509_CR25","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.ijbiomac.2014.10.021","volume":"72","author":"X He","year":"2015","unstructured":"He X, Huang Q, Qiu X, Liu X, Sun G, Guo J, et al. LAP3 promotes glioma progression by regulating proliferation, migration and invasion of glioma cells. Int J Biol Macromol. 2015;72:1081\u20139.","journal-title":"Int J Biol Macromol"},{"key":"8509_CR26","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1002\/jcb.27638","volume":"120","author":"C Fang","year":"2019","unstructured":"Fang C, Zhang J, Yang H, Peng L, Wang K, Wang Y, et al. Leucine aminopeptidase 3 promotes migration and invasion of breast cancer cells through upregulation of fascin and matrix metalloproteinases-2\/9 expression. J Cell Biochem. 2019;120:3611\u201320.","journal-title":"J Cell Biochem"},{"key":"8509_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejphar.2015.10.039","volume":"768","author":"X Wang","year":"2015","unstructured":"Wang X, Shi L, Deng Y, Qu M, Mao S, Xu L, et al. Inhibition of leucine aminopeptidase 3 suppresses invasion of ovarian cancer cells through down-regulation of fascin and MMP-2\/9. Eur J Pharm. 2015;768:116\u201322.","journal-title":"Eur J Pharm"},{"key":"8509_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s10735-014-9566-3","volume":"45","author":"S Zhang","year":"2014","unstructured":"Zhang S, Yang X, Shi H, Li M, Xue Q, Ren H, et al. Overexpression of leucine aminopeptidase 3 contributes to malignant development of human esophageal squamous cell carcinoma. J Mol Histol. 2014;45:283\u201392.","journal-title":"J Mol Histol"},{"key":"8509_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09963-w","volume":"22","author":"L Li","year":"2022","unstructured":"Li L, Li F, Hu X, Wu Z, Ren W, Wang T, et al. LAP3 contributes to IFN-\u03b3-induced arginine depletion and malignant transformation of bovine mammary epithelial cells. BMC Cancer. 2022;22:864.","journal-title":"BMC Cancer"},{"key":"8509_CR30","first-page":"1222","volume":"28","author":"W Li","year":"2021","unstructured":"Li W, Xiang S, Zeng H. LAP3 regulation of MMP-2\/9 expression on invasion and metastasis of human skin malignant melanoma cells. Labeled Immunoass Clin Med. 2021;28:1222\u201334.","journal-title":"Labeled Immunoass Clin Med"},{"key":"8509_CR31","first-page":"3752","volume":"7","author":"SY Tian","year":"2014","unstructured":"Tian SY, Chen SH, Shao BF, Cai HY, Zhou Y, Zhou YL, et al. Expression of leucine aminopeptidase 3 (LAP3) correlates with prognosis and malignant development of human hepatocellular carcinoma (HCC). Int J Clin Exp Pathol. 2014;7:3752\u201362.","journal-title":"Int J Clin Exp Pathol"},{"key":"8509_CR32","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1038\/s41388-021-01853-y","volume":"40","author":"J Wu","year":"2021","unstructured":"Wu J, Li L, Zhang H, Zhao Y, Zhang H, Wu S, et al. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma. Oncogene. 2021;40:4413\u201324.","journal-title":"Oncogene"},{"key":"8509_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/ame2.12111","volume":"3","author":"JA MacArthur Clark","year":"2020","unstructured":"MacArthur Clark JA, Sun D. Guidelines for the ethical review of laboratory animal welfare People\u2019s Republic of China National Standard GB\/T 35892-2018 [Issued 6 February 2018 Effective from 1 September 2018]. Anim Model Exp Med. 2020;3:103\u201313.","journal-title":"Anim Model Exp Med"},{"key":"8509_CR34","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.3389\/fimmu.2018.02100","volume":"9","author":"C Grasselly","year":"2018","unstructured":"Grasselly C, Denis M, Bourguignon A, Talhi N, Mathe D, Tourette A, et al. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. Front Immunol. 2018;9:2100.","journal-title":"Front Immunol"},{"key":"8509_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.immuni.2018.05.006","volume":"49","author":"C Stathopoulou","year":"2018","unstructured":"Stathopoulou C, Gangaplara A, Mallett G, Flomerfelt FA, Liniany LP, Knight D, et al. PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells. Immunity. 2018;49:247\u201363.","journal-title":"Immunity"},{"key":"8509_CR36","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12931-025-03263-0","volume":"26","author":"Q Cheng","year":"2025","unstructured":"Cheng Q, Zuo X, Wang Z, Lu W, Jiang Y, Liu J, et al. Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion. Respir Res. 2025;26:180.","journal-title":"Respir Res"},{"key":"8509_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/med.20044","volume":"26","author":"B Bauvois","year":"2006","unstructured":"Bauvois B, Dauzonne D. Aminopeptidase-N\/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev. 2006;26:88\u2013130.","journal-title":"Med Res Rev"},{"key":"8509_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cllc.2023.09.006","volume":"25","author":"S Nakamichi","year":"2024","unstructured":"Nakamichi S, Kubota K, Matsuyama K, Misumi T, Kozuki T, Sugawara S, et al. A Phase \u2161 Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q). Clin Lung Cancer. 2024;25:85\u201390.","journal-title":"Clin Lung Cancer"},{"key":"8509_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13373","volume":"56","author":"H Zhou","year":"2023","unstructured":"Zhou H, Jing S, Liu Y, Wang X, Duan X, Xiong W, et al. Identifying the key genes of Epstein-Barr virus-regulated tumour immune microenvironment of gastric carcinomas. Cell Prolif. 2023;56:e13373.","journal-title":"Cell Prolif"},{"key":"8509_CR40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/310207a0","volume":"310","author":"R Baer","year":"1984","unstructured":"Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature. 1984;310:207\u201311.","journal-title":"Nature"},{"key":"8509_CR41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4166\/kjg.2023.139","volume":"82","author":"H Jo","year":"2023","unstructured":"Jo H, Shin CM. Infectious Gastric Diseases Other than Helicobacter. Korean J Gastroenterol. 2023;82:269\u201381.","journal-title":"Korean J Gastroenterol"},{"key":"8509_CR42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5009\/gnl.2011.5.2.143","volume":"5","author":"HJ Song","year":"2011","unstructured":"Song HJ, Kim KM. Pathology of Epstein-Barr Virus-Associated Gastric Carcinoma and Its Relationship to Prognosis. Gut Liver. 2011;5:143\u20138.","journal-title":"Gut Liver"},{"key":"8509_CR43","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jare.2025.01.021","volume":"77","author":"Y Cui","year":"2025","unstructured":"Cui Y, Liu J, Wang X, Wu Y, Chang Y, Hu X, et al. Baicalin attenuates the immune escape of oral squamous cell carcinoma by reducing lactate accumulation in tumor microenvironment. J Adv Res. 2025;77:721\u201332.","journal-title":"J Adv Res"},{"key":"8509_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s11658-025-00769-9","volume":"30","author":"M Arora","year":"2025","unstructured":"Arora M, Kundu A, Sinha S, Chosdol K. Immune factors and their role in tumor aggressiveness in glioblastoma: Atypical cadherin FAT1 as a promising target for combating immune evasion. Cell Mol Biol Lett. 2025;30:89.","journal-title":"Cell Mol Biol Lett"},{"key":"8509_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s11658-024-00637-y","volume":"29","author":"L Martinkova","year":"2024","unstructured":"Martinkova L, Zatloukalova P, Kucerikova M, Friedlova N, Tylichova Z, Zavadil-Kokas F, et al. Inverse correlation between TP53 gene status and PD-L1 protein levels in a melanoma cell model depends on an IRF1\/SOX10 regulatory axis. Cell Mol Biol Lett. 2024;29:117.","journal-title":"Cell Mol Biol Lett"},{"key":"8509_CR46","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s11658-025-00786-8","volume":"30","author":"KE Shalaby","year":"2025","unstructured":"Shalaby KE, Abdelalim EM. Hypoimmune stem cells and islets: hype or a true breakthrough in diabetes treatment? Cell Mol Biol Lett. 2025;30:112.","journal-title":"Cell Mol Biol Lett"},{"key":"8509_CR47","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41392-023-01450-3","volume":"8","author":"X Ma","year":"2023","unstructured":"Ma X, Jia S, Wang G, Liang M, Guo T, Du H, et al. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance. Signal Transduct Target Ther. 2023;8:246.","journal-title":"Signal Transduct Target Ther"},{"key":"8509_CR48","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-020-0562-4","volume":"22","author":"Y Gao","year":"2020","unstructured":"Gao Y, Nihira NT, Bu X, Chu C, Zhang J, Kolodziejczyk A, et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020;22:1064\u201375.","journal-title":"Nat Cell Biol"},{"key":"8509_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22467-8","volume":"12","author":"Y Wu","year":"2021","unstructured":"Wu Y, Zhang C, Liu X, He Z, Shan B, Zeng Q, et al. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation. Nat Commun. 2021;12:2346.","journal-title":"Nat Commun"},{"key":"8509_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34346-x","volume":"13","author":"C Shi","year":"2022","unstructured":"Shi C, Wang Y, Wu M, Chen Y, Liu F, Shen Z, et al. Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation. Nat Commun. 2022;13:6951.","journal-title":"Nat Commun"},{"key":"8509_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01883-y","volume":"22","author":"Z Miao","year":"2023","unstructured":"Miao Z, Li J, Wang Y, Shi M, Gu X, Zhang X, et al. Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375\/PRKDC Axis and PD-L1 phosphorylation. Mol Cancer. 2023;22:205.","journal-title":"Mol Cancer"},{"key":"8509_CR52","doi-asserted-by":"publisher","first-page":"5170","DOI":"10.1021\/acs.langmuir.4c04441","volume":"41","author":"S Zhang","year":"2025","unstructured":"Zhang S, Wang HY, Tao X, Chen Z, Levental I, Lin X. Palmitoylation of PD-L1 Regulates Its Membrane Orientation and Immune Evasion. Langmuir. 2025;41:5170\u20138.","journal-title":"Langmuir"},{"key":"8509_CR53","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1042\/BCJ20200027","volume":"477","author":"S Singh","year":"2020","unstructured":"Singh S, Sivaraman J. Crystal structure of HECT domain of UBE3C E3 ligase and its ubiquitination activity. Biochem J. 2020;477:905\u201323.","journal-title":"Biochem J"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08509-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08509-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08509-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T17:01:32Z","timestamp":1772643692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08509-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8509"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08509-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments complied with the regulations and guidelines of the ARRIVE Guidelines 2.0. (PLoS Bio 8(6), e1000412,2010). The protocols were approved by the Animal Research Ethics Committee at the Shanxi Medical University (SYD2024048).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"241"}}